Genentech Gets FDA Hearing

Xconomy San Francisco — 

South San Francisco-based Genentech, the U.S. unit of Switzerland-based drug giant Roche, said today it has been granted a hearing in which it will get a chance to appeal the FDA’s decision to revoke the market approval of bevacizumab (Avastin) for women with breast cancer. The company will be able to make its case June 28 and 29. The drug is cleared for sale by the FDA to fight lung and colorectal cancers, and it will remain cleared for sale as a treatment for breast cancer until the FDA appeal process is complete, Genentech said.

By posting a comment, you agree to our terms and conditions.

Comments are closed.